

Our Ref: 151/2023  
MARCH 2023

## Re: Your request made under the Freedom of Information Act 2000

I would be grateful if you could please answer these questions relating to the usage of Dabrafenib + Trametinib in cancer treatment.

A) Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:

- i) Metastatic Melanoma
- ii) Adjuvant Melanoma
- iii) BRAF mutated Lung Cancer

- **Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**